YH239-EE|cas 1364488-67-4|DC Chemicals

Cas No.:	1364488-67-4
Chemical Name:	YH 239-EE;YH 239 EE
Synonyms:	YH 239-EE;YH 239 EE
SMILES:	O=C(C(N1)=C(C(N(CC2=CC=C(Cl)C=C2)C=O)C(NC(C)(C)C)=O)C3=C1C=C(Cl)C=C3)OCC
Formula:	C₂₅H₂₇Cl₂N₃O₄
M.Wt:	504.4056
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent.YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets in four AML cells (OCI-AML-3 and MOLM-13 with wt p53, NB4 with p53 mutation, and HL60 with p53 deletion).

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC10851	PK11000	PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding.
DC9504	YH239-EE	YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent
DC7314	Tenovin-3	Tenovin-3 is a small molecule activator of p53 transcriptional activity.
DC8467	RO8994	RO8994 is a potent and selective spiroindolinone MDM2 inhibitor for cancer therapy.
DC8865	RG-7112	RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
DC10070	PRIMA-1MET(APR-246)	PRIMA-1MET is methylated derivative of PRIMA-1. It can restore mutant p53 activity.
DC9902	PRIMA-1	PRIMA-1 is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
DC9257	NSC59984	NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway.The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
DC10074	MX69	MX69 is the MDM2/XIAP inhibitor, used for cancer treatment.
DC8414	MI-77301 (SAR405838)	MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.